facing sheet, certificate ,declaration,...
TRANSCRIPT
BibliographyBibliographyBibliographyBibliography
108
ABE, M., WU, Z., YAMAMOTO, M., JIN, J. J., TABARA, Y., MOGI, M., KOHARA, K.,
MIKI, T. & NAKURA, J. (2005) Association of dopamine beta-hydroxylase
polymorphism with hypertension through interaction with fasting plasma glucose in
Japanese. Hypertens Res, 28, 215-21.
ABERG, H., WETTERBERG, L., ROSS, S. B. & FRODEN, O. (1974) Dopamine-beta-
hydroxylase in hypertension. Acta Med Scand, 196, 17-20.
ABIFADEL, M., VARRET, M., RABES, J. P., ALLARD, D., OUGUERRAM, K.,
DEVILLERS, M., CRUAUD, C., BENJANNET, S., WICKHAM, L., ERLICH, D.,
DERRE, A., VILLEGER, L., FARNIER, M., BEUCLER, I., BRUCKERT, E.,
CHAMBAZ, J., CHANU, B., LECERF, J. M., LUC, G., MOULIN, P.,
WEISSENBACH, J., PRAT, A., KREMPF, M., JUNIEN, C., SEIDAH, N. G. &
BOILEAU, C. (2003) Mutations in PCSK9 cause autosomal dominant
hypercholesterolemia. Nat Genet, 34, 154-6.
ABUDU, N., BANJAW, M. Y. & LJONES, T. (1998) Kinetic studies on the activation of
dopamine beta-monooxygenase by copper and vanadium ions. Eur J Biochem, 257,
622-9.
ADACHI, M., BROWNE, D. & LEWIS, E. J. (2000) Paired-like homeodomain proteins
Phox2a/Arix and Phox2b/NBPhox have similar genetic organization and independently
regulate dopamine beta-hydroxylase gene transcription. DNA Cell Biol, 19, 539-54.
ADACHI, M. & LEWIS, E. J. (2002) The paired-like homeodomain protein, Arix, mediates
protein kinase A-stimulated dopamine beta-hydroxylase gene transcription through its
phosphorylation status. J Biol Chem, 277, 22915-24.
AFFARA, S., DENOROY, L., RENAUD, B., VINCENT, M. & SASSARD, J. (1980) Serum
dopamine-beta-hydroxylase activity in a new strain of spontaneously hypertensive rats.
Experientia, 36, 1207-8.
ALANIZ, R. C., THOMAS, S. A., PEREZ-MELGOSA, M., MUELLER, K., FARR, A. G.,
PALMITER, R. D. & WILSON, C. B. (1999) Dopamine beta-hydroxylase deficiency
impairs cellular immunity. Proc Natl Acad Sci U S A, 96, 2274-8.
ALEXANDER, N., MCCLASKEY, J. & MARONDE, R. F. (1976) Elevated plasma dopamine
beta hydroxylase activity in rats with neurogenic hypertension. Life Sci, 18, 655-61.
ALEXANDRE, J. M., LONDON, G. M., CHEVILLARD, C., LEMAIRE, P., SAFAR, M. E. &
WEISS, Y. (1975) The meaning of dopamine beta-hydroxylase in essential
hypertension. Clin Sci Mol Med, 49, 573-9.
AMIT, Z., GILL, K. & NG CHEONG TON, J. M. (1991) Attenuation of voluntary ethanol
consumption by dopamine-beta-hydroxylase inhibition (FLA-57): mediated by changes
in aversion, reinforcement or both. Alcohol, 8, 79-85.
AMIT, Z., LEVITAN, D. E. & LINDROS, K. O. (1976) Suppression of ethanol intake
following administration of dopamine-beta-hydroxylase inhibitors in rats. Arch Int
Pharmacodyn Ther, 223, 114-9.
ANDERSON, J. C., WILLIAMS, S., MCGEE, R. & SILVA, P. A. (1987) DSM-III disorders in
preadolescent children. Prevalence in a large sample from the general population. Arch
Gen Psychiatry, 44, 69-76.
ANTHONY, M. (1981) Biochemical indices of sympathetic activity in migraine. Cephalalgia,
1, 83-9.
109
ARATO, M., BAGDY, G., BLUMEL, F., PERENYI, A. & RIHMER, Z. (1983) Reduced
serum dopamine-beta-hydroxylase activity in paranoid schizophrenics.
Pharmacopsychiatria, 16, 19-22.
ARATO, M., BAGDY, G. & PERENYI, A. (1982) Reduced serum dopamine-beta-hydroxylase
activity in paranoid schizophrenia. Biol Psychiatry, 17, 853-4.
AUNIS, D., MIRAS-PORTUGAL, M. T. & MANDEL, P. (1973) Inhibition of adrenal
dopamine-beta-hydroxylase by 6-hydroxy dopamine. Biochem Pharmacol, 22, 2581-9.
BALDONI, J. M. & VILLAFRANCA, J. J. (1980) Dopamine beta-hydroxylase. Inactivation by
a suicide substrate. J Biol Chem, 255, 8987-90.
BELIAEV, A., LEARMONTH, D. A. & SOARES-DA-SILVA, P. (2006) Synthesis and
biological evaluation of novel, peripherally selective chromanyl imidazolethione-based
inhibitors of dopamine beta-hydroxylase. J Med Chem, 49, 1191-7.
BENTLEY, D. R., BALASUBRAMANIAN, S., SWERDLOW, H. P., SMITH, G. P.,
MILTON, J., BROWN, C. G., HALL, K. P., EVERS, D. J., BARNES, C. L.,
BIGNELL, H. R., BOUTELL, J. M., BRYANT, J., CARTER, R. J., KEIRA
CHEETHAM, R., COX, A. J., ELLIS, D. J., FLATBUSH, M. R., GORMLEY, N. A.,
HUMPHRAY, S. J., IRVING, L. J., KARBELASHVILI, M. S., KIRK, S. M., LI, H.,
LIU, X., MAISINGER, K. S., MURRAY, L. J., OBRADOVIC, B., OST, T.,
PARKINSON, M. L., PRATT, M. R., RASOLONJATOVO, I. M., REED, M. T.,
RIGATTI, R., RODIGHIERO, C., ROSS, M. T., SABOT, A., SANKAR, S. V.,
SCALLY, A., SCHROTH, G. P., SMITH, M. E., SMITH, V. P., SPIRIDOU, A.,
TORRANCE, P. E., TZONEV, S. S., VERMAAS, E. H., WALTER, K., WU, X.,
ZHANG, L., ALAM, M. D., ANASTASI, C., ANIEBO, I. C., BAILEY, D. M.,
BANCARZ, I. R., BANERJEE, S., BARBOUR, S. G., BAYBAYAN, P. A., BENOIT,
V. A., BENSON, K. F., BEVIS, C., BLACK, P. J., BOODHUN, A., BRENNAN, J. S.,
BRIDGHAM, J. A., BROWN, R. C., BROWN, A. A., BUERMANN, D. H., BUNDU,
A. A., BURROWS, J. C., CARTER, N. P., CASTILLO, N., CHIARA, E. C. M.,
CHANG, S., NEIL COOLEY, R., CRAKE, N. R., DADA, O. O., DIAKOUMAKOS,
K. D., DOMINGUEZ-FERNANDEZ, B., EARNSHAW, D. J., EGBUJOR, U. C.,
ELMORE, D. W., ETCHIN, S. S., EWAN, M. R., FEDURCO, M., FRASER, L. J.,
FUENTES FAJARDO, K. V., SCOTT FUREY, W., GEORGE, D., GIETZEN, K. J.,
GODDARD, C. P., GOLDA, G. S., GRANIERI, P. A., GREEN, D. E., GUSTAFSON,
D. L., HANSEN, N. F., HARNISH, K., HAUDENSCHILD, C. D., HEYER, N. I.,
HIMS, M. M., HO, J. T., HORGAN, A. M., et al. (2008) Accurate whole human
genome sequencing using reversible terminator chemistry. Nature, 456, 53-9.
BHADURI, N., SINHA, S., CHATTOPADHYAY, A., GANGOPADHYAY, P. K., SINGH,
M. & MUKHOPADHYAY, K. K. (2005) Analysis of polymorphisms in the dopamine
beta hydroxylase gene: association with attention deficit hyperactivity disorder in
Indian children. Indian Pediatr, 42, 123-9.
BIAGGIONI, I., GOLDSTEIN, D. S., ATKINSON, T. & ROBERTSON, D. (1990) Dopamine-
beta-hydroxylase deficiency in humans. Neurology, 40, 370-3.
BIAGGIONI, I. & ROBERTSON, D. (1987) Endogenous restoration of noradrenaline by
precursor therapy in dopamine-beta-hydroxylase deficiency. Lancet, 2, 1170-2.
BIEDERMAN, J., NEWCORN, J. & SPRICH, S. (1991) Comorbidity of attention deficit
hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J
Psychiatry, 148, 564-77.
110
BLACKBURN, N. J., CONCANNON, M., SHAHIYAN, S. K., MABBS, F. E. & COLLISON,
D. (1988) Active site of dopamine beta-hydroxylase. Comparison of enzyme
derivatives containing four and eight copper atoms per tetramer using potentiometry
and EPR spectroscopy. Biochemistry, 27, 6001-8.
BLACKBURN, N. J., HASNAIN, S. S., PETTINGILL, T. M. & STRANGE, R. W. (1991)
Copper K-extended x-ray absorption fine structure studies of oxidized and reduced
dopamine beta-hydroxylase. Confirmation of a sulfur ligand to copper(I) in the reduced
enzyme. J Biol Chem, 266, 23120-7.
BLACKBURN, N. J., PETTINGILL, T. M., SEAGRAVES, K. S. & SHIGETA, R. T. (1990)
Characterization of a carbon monoxide complex of reduced dopamine beta-
hydroxylase. Evidence for inequivalence of the Cu(I) centers. J Biol Chem, 265, 15383-
6.
BODMER, W. & BONILLA, C. (2008) Common and rare variants in multifactorial
susceptibility to common diseases. Nat Genet, 40, 695-701.
BON, S., LAMOUROUX, A., VIGNY, A., MASSOULIE, J., MALLET, J. & HENRY, J. P.
(1991) Amphiphilic and nonamphiphilic forms of bovine and human dopamine beta-
hydroxylase. J Neurochem, 57, 1100-11.
BOTSTEIN, D. & RISCH, N. (2003) Discovering genotypes underlying human phenotypes:
past successes for mendelian disease, future approaches for complex disease. Nat
Genet, 33 Suppl, 228-37.
BOURDELAT-PARKS, B. N., ANDERSON, G. M., DONALDSON, Z. R., WEISS, J. M.,
BONSALL, R. W., EMERY, M. S., LILES, L. C. & WEINSHENKER, D. (2005)
Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on
catecholamine homeostasis in mice. Psychopharmacology (Berl), 183, 72-80.
BOWDEN, C. L., DEUTSCH, C. K. & SWANSON, J. M. (1988) Plasma dopamine-beta-
hydroxylase and platelet monoamine oxidase in attention deficit disorder and conduct
disorder. J Am Acad Child Adolesc Psychiatry, 27, 171-4.
BRIDGERS, W. F. & KAUFMAN, S. (1962) The enzymatic conversion of epinine to
epinephrine. J Biol Chem, 237, 526-8.
BRODDE, O. E., NAGEL, M. & SCHUMANN, H. J. (1977) Mechanism of inhibition of
dopamine beta-hydroxylase evoked by FLA-63. An in vitro study. Arch Int
Pharmacodyn Ther, 228, 184-90.
BROOKE, S. M. & FIBIGER, H. C. (1976) Reserpine-induced changes in dopamine-beta-
hydroxylase activity in the terminal projections of the nucleus locus coeruleus.
Neurosci Lett, 2, 279-83.
BROOKS-WILSON, A. R., KAURAH, P., SURIANO, G., LEACH, S., SENZ, J., GREHAN,
N., BUTTERFIELD, Y. S., JEYES, J., SCHINAS, J., BACANI, J., KELSEY, M.,
FERREIRA, P., MACGILLIVRAY, B., MACLEOD, P., MICEK, M., FORD, J.,
FOULKES, W., AUSTRALIE, K., GREENBERG, C., LAPOINTE, M., GILPIN, C.,
NIKKEL, S., GILCHRIST, D., HUGHES, R., JACKSON, C. E., MONAGHAN, K. G.,
OLIVEIRA, M. J., SERUCA, R., GALLINGER, S., CALDAS, C. & HUNTSMAN, D.
(2004) Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment
of 42 new families and review of genetic screening criteria. J Med Genet, 41, 508-17.
111
BROWN, Z. W., AMIT, Z., SINYOR, D., ROCKMAN, G. E. & OGREN, S. O. (1978)
Suppression of voluntary ingestion of morphine by inhibition of dopamine-beta-
hydroxylase. Arch Int Pharmacodyn Ther, 232, 102-10.
CARGILL, M., ALTSHULER, D., IRELAND, J., SKLAR, P., ARDLIE, K., PATIL, N.,
SHAW, N., LANE, C. R., LIM, E. P., KALYANARAMAN, N., NEMESH, J.,
ZIAUGRA, L., FRIEDLAND, L., ROLFE, A., WARRINGTON, J., LIPSHUTZ, R.,
DALEY, G. Q. & LANDER, E. S. (1999) Characterization of single-nucleotide
polymorphisms in coding regions of human genes. Nat Genet, 22, 231-8.
CAROLDI, S. & DE PARIS, P. (1995) Comparative effects of two dithiocarbamates disulfiram
and thiram, on adrenal catecholamine content and on plasma dopamine-beta-
hydroxylase activity. Arch Toxicol, 69, 690-3.
CARTEGNI, L., CHEW, S. L. & KRAINER, A. R. (2002) Listening to silence and
understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet, 3, 285-
98.
CHAMARY, J. V., PARMLEY, J. L. & HURST, L. D. (2006) Hearing silence: non-neutral
evolution at synonymous sites in mammals. Nat Rev Genet, 7, 98-108.
CHAMBERS, K. J., TONKIN, L. A., CHANG, E., SHELTON, D. N., LINSKENS, M. H. &
FUNK, W. D. (1998) Identification and cloning of a sequence homologue of dopamine
beta-hydroxylase. Gene, 218, 111-20.
CHEN, Y., WEN, G., RAO, F., ZHANG, K., WANG, L., RODRIGUEZ-FLORES, J. L.,
SANCHEZ, A. P., MAHATA, M., TAUPENOT, L., SUN, P., MAHATA, S. K.,
TAYO, B., SCHORK, N. J., ZIEGLER, M. G., HAMILTON, B. A. & O'CONNOR, D.
T. (2010) Human dopamine beta-hydroxylase (DBH) regulatory polymorphism that
influences enzymatic activity, autonomic function, and blood pressure. J Hypertens, 28,
76-86.
CHEN, Y., ZHANG, K., WEN, G., RAO, F., SANCHEZ, A. P., WANG, L., RODRIGUEZ-
FLORES, J. L., MAHATA, M., MAHATA, S. K., WAALEN, J., ZIEGLER, M. G.,
HAMILTON, B. A. & O'CONNOR, D. T. (2011) Human dopamine beta-hydroxylase
promoter variant alters transcription in chromaffin cells, enzyme secretion, and blood
pressure. Am J Hypertens, 24, 24-32.
CIRULLI, E. T. & GOLDSTEIN, D. B. (2010) Uncovering the roles of rare variants in
common disease through whole-genome sequencing. Nat Rev Genet, 11, 415-25.
CLAXTON, I. M., PALFREYMAN, M. G., POYSER, R. H. & WHITING, R. L. (1976) BRL
8242 (2-[2-benzimidazolyl]-amino-2-imidazoline dihydrochloride), a new inhibitor of
dopamine-beta-hydroxylase with antihypertensive activity. Eur J Pharmacol, 37, 179-88.
COHEN, J., PERTSEMLIDIS, A., KOTOWSKI, I. K., GRAHAM, R., GARCIA, C. K. &
HOBBS, H. H. (2005) Low LDL cholesterol in individuals of African descent resulting
from frequent nonsense mutations in PCSK9. Nat Genet, 37, 161-5.
COHEN, J. C., BOERWINKLE, E., MOSLEY, T. H., JR. & HOBBS, H. H. (2006) Sequence
variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J
Med, 354, 1264-72.
COHEN, J. C., KISS, R. S., PERTSEMLIDIS, A., MARCEL, Y. L., MCPHERSON, R. &
HOBBS, H. H. (2004) Multiple rare alleles contribute to low plasma levels of HDL
cholesterol. Science, 305, 869-72.
112
COLOMBO, G., RAJASHEKHAR, B., ASH, D. E. & VILLAFRANCA, J. J. (1984a) Alternate
substrates of dopamine beta-hydroxylase. III. Stoichiometry of the inactivation reaction
with benzyl cyanides and spectroscopic investigations. J Biol Chem, 259, 1607-15.
COLOMBO, G., RAJASHEKHAR, B., GIEDROC, D. P. & VILLAFRANCA, J. J. (1984b)
Mechanism-based inhibitors of dopamine beta-hydroxylase: inhibition by 2-bromo-3-
(p-hydroxyphenyl)-1-propene. Biochemistry, 23, 3590-8.
COLOMBO, G. & VILLAFRANCA, J. J. (1984) An acetylenic mechanism-based inhibitor of
dopamine beta-hydroxylase. J Biol Chem, 259, 15017-20.
CONDE, L., BRACCI, P. M., RICHARDSON, R., MONTGOMERY, S. B. & SKIBOLA, C.
F. (2013) Integrating GWAS and expression data for functional characterization of
disease-associated SNPs: an application to follicular lymphoma. Am J Hum Genet, 92,
126-30.
COTZIAS, G. C., PAPAVASILIOU, P. S. & GELLENE, R. (1969) L-dopa in parkinson's
syndrome. N Engl J Med, 281, 272.
CREVELING, C. R., DALY, J. W., WITKOP, B. & UNDENFRIEND, S. (1962) Substrates
and inhibitors of dopamine-beta-oxidase. Biochim Biophys Acta, 64, 125-34.
CRYAN, J. F., DALVI, A., JIN, S. H., HIRSCH, B. R., LUCKI, I. & THOMAS, S. A. (2001)
Use of dopamine-beta-hydroxylase-deficient mice to determine the role of
norepinephrine in the mechanism of action of antidepressant drugs. J Pharmacol Exp
Ther, 298, 651-7.
CUBELLS, J. F., KRANZLER, H. R., MCCANCE-KATZ, E., ANDERSON, G. M.,
MALISON, R. T., PRICE, L. H. & GELERNTER, J. (2000) A haplotype at the DBH
locus, associated with low plasma dopamine beta-hydroxylase activity, also associates
with cocaine-induced paranoia. Mol Psychiatry, 5, 56-63.
CUBELLS, J. F., PRICE, L. H., MEYERS, B. S., ANDERSON, G. M., ZABETIAN, C. P.,
ALEXOPOULOS, G. S., NELSON, J. C., SANACORA, G., KIRWIN, P.,
CARPENTER, L., MALISON, R. T. & GELERNTER, J. (2002) Genotype-controlled
analysis of plasma dopamine beta-hydroxylase activity in psychotic unipolar major
depression. Biol Psychiatry, 51, 358-64.
CUBELLS, J. F., VAN KAMMEN, D. P., KELLEY, M. E., ANDERSON, G. M.,
O'CONNOR, D. T., PRICE, L. H., MALISON, R., RAO, P. A., KOBAYASHI, K.,
NAGATSU, T. & GELERNTER, J. (1998) Dopamine beta-hydroxylase: two
polymorphisms in linkage disequilibrium at the structural gene DBH associate with
biochemical phenotypic variation. Hum Genet, 102, 533-40.
CUBELLS, J. F. & ZABETIAN, C. P. (2004) Human genetics of plasma dopamine beta-
hydroxylase activity: applications to research in psychiatry and neurology.
Psychopharmacology (Berl), 174, 463-76.
DALY, G., HAWI, Z., FITZGERALD, M. & GILL, M. (1999) Mapping susceptibility loci in
attention deficit hyperactivity disorder: preferential transmission of parental alleles at
DAT1, DBH and DRD5 to affected children. Mol Psychiatry, 4, 192-6.
DAMASE-MICHEL, C., SCHMITT, L., LE QUANG, B., BAGHERI, H., MONTASTRUC, J.
L. & MORON, P. (1991) Plasma dopamine-beta-hydroxylase activity in depressed
patients: role of treatment. J Neurol Neurosurg Psychiatry, 54, 749.
113
DE PARIS, P. & CAROLDI, S. (1994) In vivo inhibition of serum dopamine-beta-hydroxylase
by CaNa2 EDTA injection. Hum Exp Toxicol, 13, 253-6.
DE PARIS, P. & CAROLDI, S. (1995) In vitro effect of dithiocarbamate pesticides and of
CaNa2EDTA on human serum dopamine-beta-hydroxylase. Biomed Environ Sci, 8,
114-21.
DEAN, E. J., DAVIS, J. C., DAVIS, R. W. & PETROV, D. A. (2008) Pervasive and persistent
redundancy among duplicated genes in yeast. PLoS Genet, 4, e1000113.
DEINUM, J., STEENBERGEN-SPANJERS, G. C., JANSEN, M., BOOMSMA, F.,
LENDERS, J. W., VAN ITTERSUM, F. J., HUCK, N., VAN DEN HEUVEL, L. P. &
WEVERS, R. A. (2004) DBH gene variants that cause low plasma dopamine beta
hydroxylase with or without a severe orthostatic syndrome. J Med Genet, 41, e38.
DEWOLF, W. E., JR., CARR, S. A., VARRICHIO, A., GOODHART, P. J., MENTZER, M.
A., ROBERTS, G. D., SOUTHAN, C., DOLLE, R. E. & KRUSE, L. I. (1988)
Inactivation of dopamine beta-hydroxylase by p-cresol: isolation and characterization
of covalently modified active site peptides. Biochemistry, 27, 9093-101.
DHAWAN, S., DUONG, L. T., ORNBERG, R. L. & FLEMING, P. J. (1987) Subunit exchange
between membranous and soluble forms of bovine dopamine beta-hydroxylase. J Biol
Chem, 262, 1869-75.
DHAWAN, S., HENSLEY, P., OSBORNE, J. C., JR. & FLEMING, P. J. (1986) Adenosine 5'-
diphosphate-dependent subunit dissociation of bovine dopamine beta-hydroxylase. J
Biol Chem, 261, 7680-4.
DILIBERTO, E. J., JR., DISTEFANO, V. & SMITH, J. C. (1973) Mechanism and kinetics of
the inhibition of dopamine-beta-hydroxylase by 2-mercaptoethylguanidine. Biochem
Pharmacol, 22, 2961-72.
DZIENNIS, S. & HABECKER, B. A. (2003) Cytokine suppression of dopamine-beta-
hydroxylase by extracellular signal-regulated kinase-dependent and -independent
pathways. J Biol Chem, 278, 15897-904.
ELAYAN, H., KENNEDY, B. & ZIEGLER, M. G. (1992) Propranolol reduces rat dopamine-
beta-hydroxylase activity and catecholamine levels. Eur J Pharmacol, 212, 259-62.
ESLER, M., FERRIER, C., LAMBERT, G., EISENHOFER, G., COX, H. & JENNINGS, G.
(1991) Biochemical evidence of sympathetic hyperactivity in human hypertension.
Hypertension, 17, III29-35.
ESLER, M. & KAYE, D. (2000) Sympathetic nervous system activation in essential
hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc
Pharmacol, 35, S1-7.
EWING, J. A., ROUSE, B. A., MUELLER, R. A. & SILVER, D. (1978) Can dopamine beta-
hydroxylase levels predict adverse reactions to disulfiram? Alcohol Clin Exp Res, 2,
93-4.
FAN, Y., HUANG, J., KIERAN, N. & ZHU, M. Y. (2009) Effects of transcription factors
Phox2 on expression of norepinephrine transporter and dopamine beta-hydroxylase in
SK-N-BE(2)C cells. J Neurochem, 110, 1502-13.
FARRINGTON, G. K., KUMAR, A. & VILLAFRANCA, J. J. (1989) Benzofurans as
mechanism-based inhibitors of dopamine beta-hydroxylase. J Med Chem, 32, 735-7.
114
FARRINGTON, G. K., KUMAR, A. & VILLAFRANCA, J. J. (1990) Active site labeling of
dopamine beta-hydroxylase by two mechanism-based inhibitors: 6-hydroxybenzofuran
and phenylhydrazine. J Biol Chem, 265, 1036-40.
FEILCHENFELD, N. B., RICHTER, H. W. & WADDELL, W. H. (1982) A time-resolved
assay of dopamine beta-hydroxylase activity utilizing high-pressure liquid
chromatography. Anal Biochem, 122, 124-8.
FEINBERG, A. P. (2007) Phenotypic plasticity and the epigenetics of human disease. Nature,
447, 433-40.
FENG, Z., ANGELETTI, R. H., LEVIN, B. E. & SABBAN, E. L. (1992) Glycosylation and
membrane insertion of newly synthesized rat dopamine beta-hydroxylase in a cell-free
system without signal cleavage. J Biol Chem, 267, 21808-15.
FENG, Z. & SABBAN, E. L. (1995a) Mutagenesis of rat dopamine beta-hydroxylase:
examination in cell-free system. J Neurochem, 64, 25-33.
FENG, Z. & SABBAN, E. L. (1995b) Regulation of the translation and processing of rat
dopamine beta-hydroxylase by metal ions in a cell free system. Biochem Mol Biol Int,
36, 339-45.
FERNANDEZ, F., COLSON, N., QUINLAN, S., MACMILLAN, J., LEA, R. A. &
GRIFFITHS, L. R. (2009) Association between migraine and a functional
polymorphism at the dopamine beta-hydroxylase locus. Neurogenetics, 10, 199-208.
FERNANDEZ, F., LEA, R. A., COLSON, N. J., BELLIS, C., QUINLAN, S. & GRIFFITHS,
L. R. (2006) Association between a 19 bp deletion polymorphism at the dopamine beta-
hydroxylase (DBH) locus and migraine with aura. J Neurol Sci, 251, 118-23.
FERRIER, C., COX, H. & ESLER, M. (1993) Elevated total body noradrenaline spillover in
normotensive members of hypertensive families. Clin Sci (Lond), 84, 225-30.
FITZPATRICK, P. F., FLORY, D. R., JR. & VILLAFRANCA, J. J. (1985) 3-Phenylpropenes
as mechanism-based inhibitors of dopamine beta-hydroxylase: evidence for a radical
mechanism. Biochemistry, 24, 2108-14.
FITZPATRICK, P. F., HARPEL, M. R. & VILLAFRANCA, J. J. (1986) Use of alternate
substrates to probe the order of substrate addition to dopamine beta-hydroxylase. Arch
Biochem Biophys, 249, 70-5.
FITZPATRICK, P. F. & VILLAFRANCA, J. J. (1986) The mechanism of inactivation of
dopamine beta-hydroxylase by hydrazines. J Biol Chem, 261, 4510-8.
FITZPATRICK, P. F. & VILLAFRANCA, J. J. (1987) Mechanism-based inhibitors of
dopamine beta-hydroxylase. Arch Biochem Biophys, 257, 231-50.
FLATMARK, T., SKOTLAND, T., LJONES, T. & INGEBRETSEN, O. C. (1978)
Fluorimetric detection of octopamine in high-performance liquid chromatography and
its application to the assay of dopamine beta-monooxygenase in human serum. J
Chromatogr, 146, 433-8.
FLEMING, P. & SAXENA, A. (1982) Reconstitution of the Membrane-bound form of
Dopamine-beta-Hydroxylase. Biophys J, 37, 99-100.
FRIEDMAN, S. & KAUFMAN, S. (1965) 3,4-dihydroxyphenylethylamine beta-hydroxylase.
Physical properties, copper content, and role of copper in the catalytic acttivity. J Biol
Chem, 240, 4763-73.
115
FRIGON, R. P. & STONE, R. A. (1978) Human plasma dopamine beta-hydroxylase.
Purification and properties. J Biol Chem, 253, 6780-6.
FUJITA, K., MARUTA, K., TERADAIRA, R., BEPPU, H., IKEGAME, M., NAGATSU, T. &
KATO, T. (1977a) Normal values for serum dopamine-beta-hydroxylase activity. Clin
Chem, 23, 1947-8.
FUJITA, K., NAGATSU, T., MARUTA, K., TERADAIRA, R., BEPPU, H., TSUJI, Y. &
KATO, T. (1977b) Fluorescence assay for dopamine beta-hydroxylase activity in
human serum by high-performance liquid chromatography. Anal Biochem, 82, 130-40.
GANGULY, P. K., LEE, S. L. & WAGHRAY, G. (1990) Modulation of cardiac beta-adrenergic
receptors by dopamine beta-hydroxylase. Biochim Biophys Acta, 1055, 186-8.
GIBSON, G. (2012) Rare and common variants: twenty arguments. Nat Rev Genet, 13, 135-45.
GOLDSTEIN, D. J. & CUBEDDU, L. X. (1976) Dopamine-beta-hydroxylase activity in human
cerebrospinal fluid. J Neurochem, 26, 193-5.
GOLDSTEIN, M., ANAGNOSTE, B., LAUBER, E. & MCKEREGHAM, M. R. (1964a)
Inhibition of Dopamine-Beta-Hydroxylase by Disulfiram. Life Sci, 3, 763-7.
GOLDSTEIN, M., FREEDMAN, L. S. & BONNAY, M. (1971) An assay for dopamine-beta-
hydroxylase activity in tissues and serum. Experientia, 27, 632-3.
GOLDSTEIN, M., LAUBER, E. & MCKEREGHAN, M. R. (1964b) The Inhibition of
Dopamine-Beta-Hydroxylase by Tropolone and Other Chelating Agents. Biochem
Pharmacol, 13, 1103-6.
GOODHART, P. J., DEWOLF, W. E., JR. & KRUSE, L. I. (1987) Mechanism-based
inactivation of dopamine beta-hydroxylase by p-cresol and related alkylphenols.
Biochemistry, 26, 2576-83.
GOODWIN, F. K. & SACK, R. L. (1974) Behavioral effects of a new dopamine-beta-
hydroxylase inhibitor (fusaric acid) in man. J Psychiatr Res, 11, 211-7.
GOTOH, F., KANDA, T., SAKAI, F., YAMAMOTO, M. & TAKEOKA, T. (1976) Serum
dopamine-beta-hydroxylase activity in migraine. Arch Neurol, 33, 656-7.
GRASSI, G., BOLLA, G., QUARTI-TREVANO, F., ARENARE, F., BRAMBILLA, G. &
MANCIA, G. (2008) Sympathetic activation in congestive heart failure: reproducibility
of neuroadrenergic markers. Eur J Heart Fail, 10, 1186-91.
GRASSI, G., SERAVALLE, G. & QUARTI-TREVANO, F. (2010) The 'neuroadrenergic
hypothesis' in hypertension: current evidence. Exp Physiol, 95, 581-6.
GRECO, D., ZELLMER, E., ZHANG, Z. & LEWIS, E. (1995) Transcription factor AP-2
regulates expression of the dopamine beta-hydroxylase gene. J Neurochem, 65, 510-6.
HALUSHKA, M. K., FAN, J. B., BENTLEY, K., HSIE, L., SHEN, N., WEDER, A.,
COOPER, R., LIPSHUTZ, R. & CHAKRAVARTI, A. (1999) Patterns of single-
nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat
Genet, 22, 239-47.
HARRALSON, J. D., WOLFE, B. I. & BROWN, F. C. (1978) Inhibition of dopamine beta-
hydroxylase by 4-hydroxypyrazole: ethanol-pyrazole effects on serum dopamine beta-
hydroxylase in vivo. J Pharmacol Exp Ther, 206, 69-74.
116
HASHIMOTO, Y. & MIYAZAKI, H. (1979) Simultaneous determination of endogenous
norepinephrine and dopamine-beta-hydroxylase activity in biological materials by
chemical ionization mass fragmentography. J Chromatogr, 168, 59-68.
HASSAN, S., DUONG, B., KIM, K. S. & MILES, M. F. (2003) Pharmacogenomic analysis of
mechanisms mediating ethanol regulation of dopamine beta-hydroxylase. J Biol Chem,
278, 38860-9.
HATANAKA, H., EGAMI, F., KATO, T. & NAGATSU, T. (1975) Ascorbate 2-sulfate inhibits
dopamine beta-hydroxylase reaction, but not ascorbate oxidase reaction. J Biochem, 78,
821-4.
HEALY, D. G., ABOU-SLEIMAN, P. M., OZAWA, T., LEES, A. J., BHATIA, K., AHMADI,
K. R., WULLNER, U., BERCIANO, J., MOLLER, J. C., KAMM, C., BURK, K.,
BARONE, P., TOLOSA, E., QUINN, N., GOLDSTEIN, D. B. & WOOD, N. W.
(2004) A functional polymorphism regulating dopamine beta-hydroxylase influences
against Parkinson's disease. Ann Neurol, 55, 443-6.
HEGDE, S. S. & FRIDAY, K. F. (1998) Dopamine-beta-hydroxylase inhibition: a novel
sympatho-modulatory approach for the treatment of congestive heart failure. Curr
Pharm Des, 4, 469-79.
HENEKA, M. T., GALEA, E., GAVRILUYK, V., DUMITRESCU-OZIMEK, L.,
DAESCHNER, J., O'BANION, M. K., WEINBERG, G., KLOCKGETHER, T. &
FEINSTEIN, D. L. (2002) Noradrenergic depletion potentiates beta -amyloid-induced
cortical inflammation: implications for Alzheimer's disease. J Neurosci, 22, 2434-42.
HESS, C., REIF, A., STROBEL, A., BOREATTI-HUMMER, A., HEINE, M., LESCH, K. P.
& JACOB, C. P. (2009) A functional dopamine-beta-hydroxylase gene promoter
polymorphism is associated with impulsive personality styles, but not with affective
disorders. J Neural Transm, 116, 121-30.
HIDAKA, H. (1971) Fusaric (5-butylpicolinic) acid, an inhibitor of dopamine beta-hydroxylase,
affects serotonin and noradrenaline. Nature, 231, 54-5.
HIDAKA, H., NAGATSU, T., TAKEYA, K., TAKEUCHI, T. & SUDA, H. (1969) Fusaric
acid, a hypotensive agent produced by fungi. J Antibiot (Tokyo), 22, 228-30.
HIDAKA, H. & TAKEYA, K. (1972) Blood pressure decreased by halobutylpicolinic acid, an
inhibitor of dopamine beta-hydroxylase. Nature, 239, 334-5.
HONG, S. J., CHAE, H., LARDARO, T., HONG, S. & KIM, K. S. (2008a) Trim11 increases
expression of dopamine beta-hydroxylase gene by interacting with Phox2b. Biochem
Biophys Res Commun, 368, 650-5.
HONG, S. J., CHOI, H. J., HONG, S., HUH, Y., CHAE, H. & KIM, K. S. (2008b)
Transcription factor GATA-3 regulates the transcriptional activity of dopamine beta-
hydroxylase by interacting with Sp1 and AP4. Neurochem Res, 33, 1821-31.
HORWITZ, L. D. & TRAVIS, V. L. (1978) Low serum dopamine beta-hydroxylase activity. A
marker of congestive heart failure. J Clin Invest, 62, 899-906.
HUSZTI, Z., SZILAGYI, G. & KASZTREINER, E. (1983) Tyrosine hydroxylase and
dopamine beta-hydroxylase inhibiting properties of a new series of pyridazinyl
hydrazones. Biochem Pharmacol, 32, 627-36.
117
HWANG, D. Y., HWANG, M. M., KIM, H. S. & KIM, K. S. (2005) Genetically engineered
dopamine beta-hydroxylase gene promoters with better PHOX2-binding sites drive
significantly enhanced transgene expression in a noradrenergic cell-specific manner.
Mol Ther, 11, 132-41.
HWANG, O. & LEE, J. D. (1995) Reduction of dopamine beta-hydroxylase gene expression by
calcium in bovine chromaffin cells. Biochem Biophys Res Commun, 211, 864-71.
IKENO, T., HASHIMOTO, S., KUZUYA, H. & NAGATSU, T. (1977) Purification and
properties of human serum dopamine-beta-hydroxylase. Mol Cell Biochem, 18, 117-23.
ISHIGURO, H., KIM, K. S. & JOH, T. H. (1995) Identification of a negative regulatory
element in the 5'-flanking region of the human dopamine beta-hydroxylase gene. Brain
Res Mol Brain Res, 34, 251-61.
ISHIGURO, H., KIM, K. T., JOH, T. H. & KIM, K. S. (1993) Neuron-specific expression of
the human dopamine beta-hydroxylase gene requires both the cAMP-response element
and a silencer region. J Biol Chem, 268, 17987-94.
ISHIGURO, H., YAMADA, K., ICHINO, N. & NAGATSU, T. (1998) Identification and
characterization of a novel phorbol ester-responsive DNA sequence in the 5'-flanking
region of the human dopamine beta-hydroxylase gene. J Biol Chem, 273, 21941-9.
ISHII, A., KOBAYASHI, K., KIUCHI, K. & NAGATSU, T. (1991) Expression of two forms
of human dopamine-beta-hydroxylase in COS cells. Neurosci Lett, 125, 25-8.
ISHII, Y., MIMURA, C. & HOMMA, M. (1976) Effect of dopamine-beta-hydroxylase
inhibitors on blood pressure and cardiac norepinephrine levels in rats subjected to
immobilization stress. J Pharmacol Exp Ther, 198, 589-95.
ISOBE, K., YUKIMASA, N., NAKAI, T. & TAKUWA, Y. (1996) Pituitary adenylate cyclase-
activating polypeptide induces gene expression of the catecholamine synthesizing
enzymes, tyrosine hydroxylase, and dopamine beta-hydroxylase in cultured porcine
adrenal medullary chromaffin cells. Ann N Y Acad Sci, 805, 464-9.
IZUMI, H., HAYAKARI, M., KONDO, Y. & TAKEMOTO, T. (1975) Inhibition of dopamine-
beta-hydroxylase by carnosine. Tohoku J Exp Med, 117, 101-2.
IZUMI, H., HAYAKARI, M. & OZAWA, H. (1976a) Further studies on irreversible inhibition
of dopamine-beta-hydroxylase by cysteine. Tohoku J Exp Med, 118, 373-80.
IZUMI, H., OYAMA, H., HAYAKARI, M. & OZAWA, H. (1976b) Irreversible inhibition of
dopamine-beta-hydroxylase by cysteine. Biochem Pharmacol, 25, 488-9.
IZUMI, H., OYAMA, H., HAYAKARI, M. & OZAWA, K. (1976c) Different patterns of
inhibition of dopamine-beta-hydroxylase by cysteine. Jpn J Pharmacol, 26, 263-6.
JABLONKA, E. & RAZ, G. (2009) Transgenerational epigenetic inheritance: prevalence,
mechanisms, and implications for the study of heredity and evolution. Q Rev Biol, 84,
131-76.
JAMES, A. & JORGENSEN, C. (2010) Basic design of MRM assays for peptide
quantification. Methods Mol Biol, 658, 167-85.
JELLINGER, K., KIENZL, E., RUMPELMAIR, G., RIEDERER, P., STACHELBERGER, H.,
BEN-SHACHAR, D. & YOUDIM, M. B. (1992) Iron-melanin complex in substantia
nigra of parkinsonian brains: an x-ray microanalysis. J Neurochem, 59, 1168-71.
118
JENSEN, P. S., MARTIN, D. & CANTWELL, D. P. (1997) Comorbidity in ADHD:
implications for research, practice, and DSM-V. J Am Acad Child Adolesc Psychiatry,
36, 1065-79.
JOH, T. H., ROSS, R. A. & REIS, D. J. (1974) A simple and sensitive assay for dopamine-beta-
hydroxylase. Anal Biochem, 62, 248-54.
JOHNSON, G. A., BOUKMA, S. J. & KIM, E. G. (1969) Inhibition of dopamine beta-
hydroxylase by aromatic and alkyl thioureas. J Pharmacol Exp Ther, 168, 229-34.
JOHNSON, G. A., BOUKMA, S. J. & KIM, E. G. (1970) In vivo inhibition of dopamine beta-
hydroxylase by 1-phenyl-3-(2-thiazolyl)-2-thiourea (U-14,624). J Pharmacol Exp Ther,
171, 80-7.
JOSE, P. A., EISNER, G. M. & FELDER, R. A. (2002) Role of dopamine receptors in the
kidney in the regulation of blood pressure. Curr Opin Nephrol Hypertens, 11, 87-92.
JUYAL, R. C., DAS, M., PUNIA, S., BEHARI, M., NAINWAL, G., SINGH, S.,
SWAMINATH, P. V., GOVINDAPPA, S. T., JAYARAM, S., MUTHANE, U. B. &
THELMA, B. K. (2006) Genetic susceptibility to Parkinson's disease among South and
North Indians: I. Role of polymorphisms in dopamine receptor and transporter genes
and association of DRD4 120-bp duplication marker. Neurogenetics, 7, 223-9.
KANETSKY, P. A., GE, F., NAJARIAN, D., SWOYER, J., PANOSSIAN, S., SCHUCHTER,
L., HOLMES, R., GUERRY, D. & REBBECK, T. R. (2004) Assessment of
polymorphic variants in the melanocortin-1 receptor gene with cutaneous pigmentation
using an evolutionary approach. Cancer Epidemiol Biomarkers Prev, 13, 808-19.
KAPOOR, A., SHANDILYA, M. & KUNDU, S. (2011) Structural insight of dopamine beta-
hydroxylase, a drug target for complex traits, and functional significance of exonic
single nucleotide polymorphisms. PLoS One, 6, e26509.
KARAHASANOGLU, A. M., OZAND, P. T., DIGGS, D. & TILDON, J. T. (1975) A modified
method for the measurement of dopamine beta-hydroxylase. Anal Biochem, 66, 523-31.
KATO, T., KUZUYA, H. & NAGATSU, T. (1974) A simple and sensitive assay for dopamine-
beta-hydroxylase activity by dual-wavelength spectrophotometry. Biochem Med, 10, 320-8.
KATO, T., NAGATSU, T., HASHIMOTO, Y., NUMATA-SUDO, Y., YAMORI, Y. &
OKAMOTO, K. (1978) Dopamine beta-hydroxylase activity in stroke-prone
spontaneously hypertensive rats. Jpn Heart J, 19, 641.
KAUFMAN, S. (1966) Coenzymes and hydroxylases: ascorbate and dopamine-beta-
hydroxylase; tetrahydropteridines and phenylalanine and tyrosine hydroxylases.
Pharmacol Rev, 18, 61-9.
KAUFMAN, S., BRIDGERS, W. F., EISENBERG, F. & FRIEDMAN, S. (1962) The source of
oxygen in the phenylalanine hydroxylase and the dopamine-beta-hydroxylase catalyzed
rections. Biochem Biophys Res Commun, 9, 497-502.
KAUFMAN, S. & FRIEDMAN, S. (1965) Dopamine-Beta-Hydroxylase. Pharmacol Rev, 17,
71-100.
KIM, C. H., LEUNG, A., HUH, Y. H., YANG, E., KIM, D. J., LEBLANC, P., RYU, H., KIM,
K., KIM, D. W., GARLAND, E. M., RAJ, S. R., BIAGGIONI, I., ROBERTSON, D. &
KIM, K. S. (2011) Norepinephrine deficiency is caused by combined abnormal mRNA
processing and defective protein trafficking of dopamine beta-hydroxylase. J Biol
Chem, 286, 9196-204.
119
KIM, C. H., ZABETIAN, C. P., CUBELLS, J. F., CHO, S., BIAGGIONI, I., COHEN, B. M.,
ROBERTSON, D. & KIM, K. S. (2002) Mutations in the dopamine beta-hydroxylase
gene are associated with human norepinephrine deficiency. Am J Med Genet, 108, 140-7.
KIM, H. S., HONG, S. J., LEDOUX, M. S. & KIM, K. S. (2001) Regulation of the tyrosine
hydroxylase and dopamine beta-hydroxylase genes by the transcription factor AP-2. J
Neurochem, 76, 280-94.
KIM, H. S., SEO, H., YANG, C., BRUNET, J. F. & KIM, K. S. (1998a) Noradrenergic-specific
transcription of the dopamine beta-hydroxylase gene requires synergy of multiple cis-
acting elements including at least two Phox2a-binding sites. J Neurosci, 18, 8247-60.
KIM, H. S., YANG, C. & KIM, K. S. (1998b) The cell-specific silencer region of the human
dopamine beta-hydroxylase gene contains several negative regulatory elements. J
Neurochem, 71, 41-50.
KIM, K. S., ISHIGURO, H., TINTI, C., WAGNER, J. & JOH, T. H. (1994) The cAMP-
dependent protein kinase regulates transcription of the dopamine beta-hydroxylase
gene. J Neurosci, 14, 7200-7.
KIMCHI-SARFATY, C., OH, J. M., KIM, I. W., SAUNA, Z. E., CALCAGNO, A. M.,
AMBUDKAR, S. V. & GOTTESMAN, M. M. (2007) A "silent" polymorphism in the
MDR1 gene changes substrate specificity. Science, 315, 525-8.
KIMURA, M. (1977) Preponderance of synonymous changes as evidence for the neutral theory
of molecular evolution. Nature, 267, 275-6.
KIRLEY, A., HAWI, Z., DALY, G., MCCARRON, M., MULLINS, C., MILLAR, N.,
WALDMAN, I., FITZGERALD, M. & GILL, M. (2002) Dopaminergic system genes
in ADHD: toward a biological hypothesis. Neuropsychopharmacology, 27, 607-19.
KIRSHNER, N., SCHANBERG, S. M. & SAGE, H. J. (1975) Homospecific activity of serum
and tissue dopamine-beta-hydroxylase. Life Sci, 17, 423-9.
KLINMAN, J. P., HUMPHRIES, H. & VOET, J. G. (1980) Deduction of kinetic mechanism in
multisubstrate enzyme reactions from tritium isotope effects. Application to dopamine
beta-hydroxylase. J Biol Chem, 255, 11648-51.
KLINMAN, J. P. & KRUEGER, M. (1982) Dopamine beta-hydroxylase: activity and inhibition
in the presence of beta-substituted phenethylamines. Biochemistry, 21, 67-75.
KOBAYASHI, K., KUROSAWA, Y., FUJITA, K. & NAGATSU, T. (1989) Human dopamine
beta-hydroxylase gene: two mRNA types having different 3'-terminal regions are
produced through alternative polyadenylation. Nucleic Acids Res, 17, 1089-102.
KOHNKE, M. D., KOLB, W., KOHNKE, A. M., LUTZ, U., SCHICK, S. & BATRA, A.
(2006) DBH*444G/A polymorphism of the dopamine-beta-hydroxylase gene is
associated with alcoholism but not with severe alcohol withdrawal symptoms. J Neural
Transm, 113, 869-76.
KOHNKE, M. D., ZABETIAN, C. P., ANDERSON, G. M., KOLB, W., GAERTNER, I.,
BUCHKREMER, G., VONTHEIN, R., SCHICK, S., LUTZ, U., KOHNKE, A. M. &
CUBELLS, J. F. (2002) A genotype-controlled analysis of plasma dopamine beta-
hydroxylase in healthy and alcoholic subjects: evidence for alcohol-related differences
in noradrenergic function. Biol Psychiatry, 52, 1151-8.
120
KONG, A., STEINTHORSDOTTIR, V., MASSON, G., THORLEIFSSON, G., SULEM, P.,
BESENBACHER, S., JONASDOTTIR, A., SIGURDSSON, A., KRISTINSSON, K.
T., FRIGGE, M. L., GYLFASON, A., OLASON, P. I., GUDJONSSON, S. A.,
SVERRISSON, S., STACEY, S. N., SIGURGEIRSSON, B., BENEDIKTSDOTTIR,
K. R., SIGURDSSON, H., JONSSON, T., BENEDIKTSSON, R., OLAFSSON, J. H.,
JOHANNSSON, O. T., HREIDARSSON, A. B., SIGURDSSON, G., FERGUSON-
SMITH, A. C., GUDBJARTSSON, D. F., THORSTEINSDOTTIR, U. &
STEFANSSON, K. (2009) Parental origin of sequence variants associated with
complex diseases. Nature, 462, 868-74.
KOPECKOVA, M., PACLT, I. & GOETZ, P. (2006a) Polymorphisms and low plasma activity
of dopamine-beta-hydroxylase in ADHD children. Neuro Endocrinol Lett, 27, 748-54.
KOPECKOVA, M., PACLT, I. & GOETZ, P. (2006b) Polymorphisms of dopamine-beta-
hydroxylase in ADHD children. Folia Biol (Praha), 52, 194-201.
KRUSE, L. I., DEWOLF, W. E., JR., CHAMBERS, P. A. & GOODHART, P. J. (1986a)
Design and kinetic characterization of multisubstrate inhibitors of dopamine beta-
hydroxylase. Biochemistry, 25, 7271-8.
KRUSE, L. I., KAISER, C., DEWOLF, W. E., FINKELSTEIN, J. A., FRAZEE, J. S.,
HILBERT, E. L., ROSS, S. T., FLAIM, K. E. & SAWYER, J. L. (1990) Some benzyl-
substituted imidazoles, triazoles, tetrazoles, pyridinethiones, and structural relatives as
multisubstrate inhibitors of dopamine beta-hydroxylase. 4. Structure-activity
relationships at the copper binding site. J Med Chem, 33, 781-9.
KRUSE, L. I., KAISER, C., DEWOLF, W. E., JR., CHAMBERS, P. A., GOODHART, P. J.,
EZEKIEL, M. & OHLSTEIN, E. H. (1988) Beta-substituted phenethylamines as high-
affinity mechanism-based inhibitors of dopamine beta-hydroxylase. J Med Chem, 31,
704-6.
KRUSE, L. I., KAISER, C., DEWOLF, W. E., JR., FRAZEE, J. S., ERICKSON, R. W.,
EZEKIEL, M., OHLSTEIN, E. H., RUFFOLO, R. R., JR. & BERKOWITZ, B. A.
(1986b) Substituted 1-benzylimidazole-2-thiols as potent and orally active inhibitors of
dopamine beta-hydroxylase. J Med Chem, 29, 887-9.
KRUSE, L. I., KAISER, C., DEWOLF, W. E., JR., FRAZEE, J. S., GARVEY, E., HILBERT,
E. L., FAULKNER, W. A., FLAIM, K. E., SAWYER, J. L. & BERKOWITZ, B. A.
(1986c) Multisubstrate inhibitors of dopamine beta-hydroxylase. 1. Some 1-phenyl and
1-phenyl-bridged derivatives of imidazole-2-thione. J Med Chem, 29, 2465-72.
KRUSE, L. I., KAISER, C., DEWOLF, W. E., JR., FRAZEE, J. S., ROSS, S. T., WAWRO, J.,
WISE, M., FLAIM, K. E., SAWYER, J. L., ERICKSON, R. W. & ET AL. (1987)
Multisubstrate inhibitors of dopamine beta-hydroxylase. 2. Structure-activity
relationships at the phenethylamine binding site. J Med Chem, 30, 486-94.
KUMAR, P., HENIKOFF, S. & NG, P. C. (2009) Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm. Nat Protoc, 4,
1073-81.
LADURON, P. (1975a) Scope and limitation in dopamine beta-hydroxylase measurement.
Biochem Pharmacol, 24, 557-61.
LADURON, P. M. (1975b) Evidence for a localization of dopamine-beta-hydroxylase within
the chromaffin granules. FEBS Lett, 52, 132-4.
121
LAMOUROUX, A., HOUHOU, L., BIGUET, N. F., SERCK-HANSSEN, G., GUIBERT, B.,
ICARD-LIEPKALNS, C. & MALLET, J. (1993) Analysis of the human dopamine
beta-hydroxylase promoter: transcriptional induction by cyclic AMP. J Neurochem, 60,
364-7.
LANDER, E. S. (1996) The new genomics: global views of biology. Science, 274, 536-9.
LANDER, E. S. (2011) Initial impact of the sequencing of the human genome. Nature, 470,
187-97.
LAU, C. & SLOTKIN, T. A. (1976) Indirect and direct inhibition of dopamine beta-
hydroxylase by amphetamine in storage vesicles and synaptosomes. Br J Pharmacol,
57, 223-8.
LEA, R. A., DOHY, A., JORDAN, K., QUINLAN, S., BRIMAGE, P. J. & GRIFFITHS, L. R.
(2000) Evidence for allelic association of the dopamine beta-hydroxylase gene (DBH)
with susceptibility to typical migraine. Neurogenetics, 3, 35-40.
LEE, C. S. & TKACS, N. C. (2008) Current concepts of neurohormonal activation in heart
failure: mediators and mechanisms. AACN Adv Crit Care, 19, 364-85; quiz 386-7.
LEHNER, B. (2011) Molecular mechanisms of epistasis within and between genes. Trends
Genet, 27, 323-31.
LEVIN, E. Y. & KAUFMAN, S. (1961) Studies on the enzyme catalyzing the conversion of
3,4-dihydroxyphenylethylamine to norepinephrine. J Biol Chem, 236, 2043-9.
LEVIN, E. Y., LEVENBERG, B. & KAUFMAN, S. (1960) The enzymatic conversion of 3,4-
dihydroxyphenylethylamine to norepinephrine. J Biol Chem, 235, 2080-6.
LEWIS, D. A., HAYES, T. L., LUND, J. S. & OETH, K. M. (1992) Dopamine and the neural
circuitry of primate prefrontal cortex: implications for schizophrenia research.
Neuropsychopharmacology, 6, 127-34.
LI, B., TSING, S., KOSAKA, A. H., NGUYEN, B., OSEN, E. G., BACH, C., CHAN, H. &
BARNETT, J. (1996) Expression of human dopamine beta-hydroxylase in Drosophila
Schneider 2 cells. Biochem J, 313 ( Pt 1), 57-64.
LIPCSEY, A. (1981) [The dopamine theory of schizophrenia: reduced serum dopamine beta
hydroxylase activity in paranoid schizophrenia]. Orv Hetil, 122, 483.
LIVINGSTON, R. J., VON NIEDERHAUSERN, A., JEGGA, A. G., CRAWFORD, D. C.,
CARLSON, C. S., RIEDER, M. J., GOWRISANKAR, S., ARONOW, B. J., WEISS,
R. B. & NICKERSON, D. A. (2004) Pattern of sequence variation across 213
environmental response genes. Genome Res, 14, 1821-31.
LJONES, T. & FLATMARK, T. (1974) Dopamine beta-hydroxylase: evidence against a ping-
pong mechanism. FEBS Lett, 49, 49-52.
LOTTI, V. J., TORCHIANA, M. L. & STONE, C. A. (1977) The anticonvulsant action of
methazolamide in mice: antagonism by various inhibitors of dopamine beta-
hydroxylase. Eur J Pharmacol, 44, 387-90.
LYNESS, S. A., ZAROW, C. & CHUI, H. C. (2003) Neuron loss in key cholinergic and
aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol Aging, 24, 1-23.
MACDONALD, E. & PISPA, J. P. (1977) Evidence for inhibition of dopamine-beta-
hydroxylase in vivo after sub-acute pyrazole treatment in rats. Med Biol, 55, 284-91.
122
MACKAY, T. F. (2001) The genetic architecture of quantitative traits. Annu Rev Genet, 35,
303-39.
MACKAY, T. F., STONE, E. A. & AYROLES, J. F. (2009) The genetics of quantitative traits:
challenges and prospects. Nat Rev Genet, 10, 565-77.
MAHER, B. (2008) Personal genomes: The case of the missing heritability. Nature, 456, 18-21.
MAN IN 'T VELD, A., BOOMSMA, F., LENDERS, J., VD MEIRACKER, A., JULIEN, C.,
TULEN, J., MOLEMAN, P., THIEN, T., LAMBERTS, S. & SCHALEKAMP, M.
(1988a) Patients with congenital dopamine beta-hydroxylase deficiency. A lesson in
catecholamine physiology. Am J Hypertens, 1, 231-8.
MAN IN 'T VELD, A. J., BOOMSMA, F., MOLEMAN, P. & SCHALEKAMP, M. A. (1987a)
Congenital dopamine-beta-hydroxylase deficiency. A novel orthostatic syndrome.
Lancet, 1, 183-8.
MAN IN 'T VELD, A. J., BOOMSMA, F., VAN DEN MEIRACKER, A. H., JULIEN, C.,
LENDERS, J. & SCHALEKAMP, M. A. (1988b) d,l-threo-3,4-dihydroxyphenylserine
restores sympathetic control and cures orthostatic hypotension in dopamine beta-
hydroxylase deficiency. J Hypertens Suppl, 6, S547-9.
MAN IN 'T VELD, A. J., BOOMSMA, F., VAN DEN MEIRACKER, A. H. &
SCHALEKAMP, M. A. (1987b) Effect of unnatural noradrenaline precursor on
sympathetic control and orthostatic hypotension in dopamine-beta-hydroxylase
deficiency. Lancet, 2, 1172-5.
MANCIA, G., GRASSI, G., GIANNATTASIO, C. & SERAVALLE, G. (1999) Sympathetic
activation in the pathogenesis of hypertension and progression of organ damage.
Hypertension, 34, 724-8.
MANOLIO, T. A., COLLINS, F. S., COX, N. J., GOLDSTEIN, D. B., HINDORFF, L. A.,
HUNTER, D. J., MCCARTHY, M. I., RAMOS, E. M., CARDON, L. R.,
CHAKRAVARTI, A., CHO, J. H., GUTTMACHER, A. E., KONG, A., KRUGLYAK,
L., MARDIS, E., ROTIMI, C. N., SLATKIN, M., VALLE, D., WHITTEMORE, A. S.,
BOEHNKE, M., CLARK, A. G., EICHLER, E. E., GIBSON, G., HAINES, J. L.,
MACKAY, T. F., MCCARROLL, S. A. & VISSCHER, P. M. (2009) Finding the
missing heritability of complex diseases. Nature, 461, 747-53.
MARKIANOS, E. S. & RUTHER, E. (1977) Serum dopamine-beta-hydroxylase in
parkinsonism. J Neural Transm, 40, 21-5.
MATEO, I., INFANTE, J., RODRIGUEZ, E., BERCIANO, J., COMBARROS, O. &
LLORCA, J. (2006) Interaction between dopamine beta-hydroxylase and interleukin
genes increases Alzheimer's disease risk. J Neurol Neurosurg Psychiatry, 77, 278-9.
MATSUI, H., KATO, T., YAMAMOTO, C., TAKITA, T., TAKEUCHI, T., UMEZAWA, H.
& NAGATSU, T. (1980) Inhibition of dopamine-beta-hydroxylase, A copper enzyme,
by bleomycin. J Antibiot (Tokyo), 33, 435-40.
MAY, S. W., PHILLIPS, R. S., MUELLER, P. W. & HERMAN, H. H. (1981a) Dopamine
beta-hydroxylase. Comparative specificities and mechanisms of the oxygenation
reactions. J Biol Chem, 256, 8470-5.
MAY, S. W., PHILLIPS, R. S., MUELLER, P. W. & HERMAN, H. H. (1981b) Dopamine
beta-hydroxylase. Demonstration of enzymatic ketonization of the product enantiomer
S-octopamine. J Biol Chem, 256, 2258-61.
123
MCCRACKEN, J., DESAI, P. R., PAPADOPOULOS, N. J., VILLAFRANCA, J. J. &
PEISACH, J. (1988) Electron spin-echo studies of the copper(II) binding sites in
dopamine beta-hydroxylase. Biochemistry, 27, 4133-7.
MCLOUGHLIN, S. Y. & COPLEY, S. D. (2008) A compromise required by gene sharing
enables survival: Implications for evolution of new enzyme activities. Proc Natl Acad
Sci U S A, 105, 13497-502.
MELTZER, H. Y., CHO, H. W., CARROLL, B. J. & RUSSO, P. (1976) Serum dopamine-beta-
hydroxylase activity in the affective psychoses and schizophrenia. Decreased activity in
unipolar psychotically depressed patients. Arch Gen Psychiatry, 33, 585-91.
MENNITI, F. S., KNOTH, J., PETERSON, D. S. & DILIBERTO, E. J., JR. (1987) The in situ
kinetics of dopamine beta-hydroxylase in bovine adrenomedullary chromaffin cells.
Intravesicular compartmentation reduces apparent affinity for the cofactor ascorbate. J
Biol Chem, 262, 7651-7.
MEYERS, B. S., ALEXOPOULOS, G. S., KAKUMA, T., TIRUMALASETTI, F.,
GABRIELE, M., ALPERT, S., BOWDEN, C. & MELTZER, H. Y. (1999) Decreased
dopamine beta-hydroxylase activity in unipolar geriatric delusional depression. Biol
Psychiatry, 45, 448-52.
MILANESE, M., LKHAYAT, M. I. & ZATTA, P. (2001) Inhibitory effect of aluminum on
dopamine beta-hydroxylase from bovine adrenal gland. J Trace Elem Med Biol, 15,
139-41.
MILLER, M. P. & KUMAR, S. (2001) Understanding human disease mutations through the use
of interspecific genetic variation. Hum Mol Genet, 10, 2319-28.
MIYANO, K., SAKASAI, T. & HAMANO, H. (1978) Synthesis of 5-(substituted alkyl)
picolinic acids. The dopamine beta-hydroxylase inhibitors. II. Chem Pharm Bull
(Tokyo), 26, 2328-33.
MIYATA, S., NAGATA, H., YAMAO, S., NAKAMURA, S. & KAMEYAMA, M. (1984)
Dopamine-beta-hydroxylase activities in serum and cerebrospinal fluid of aged and
demented patients. J Neurol Sci, 63, 403-9.
MOLINOFF, P. B., WEINSHILBOUM, R. & AXELROD, J. (1971) A sensitive enzymatic
assay for dopamine- -hydroxylase. J Pharmacol Exp Ther, 178, 425-31.
MUSACCHIO, J. M., GOLDSTEIN, M., ANAGNOSTE, B., POCH, G. & KOPIN, I. J. (1966)
Inhibition of dopamine-beta-hydroxylase by disulfiram in vivo. J Pharmacol Exp Ther,
152, 56-61.
MUSSO, G., COSTANZO, M., HUANGFU, M., SMITH, A. M., PAW, J., SAN LUIS, B. J.,
BOONE, C., GIAEVER, G., NISLOW, C., EMILI, A. & ZHANG, Z. (2008) The
extensive and condition-dependent nature of epistasis among whole-genome duplicates
in yeast. Genome Res, 18, 1092-9.
MUSTAPIC, M., PRESECKI, P., PIVAC, N., MIMICA, N., HOF, P. R., SIMIC, G.,
FOLNEGOVIC-SMALC, V. & MUCK-SELER, D. (2013) Genotype-independent
decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease. Prog
Neuropsychopharmacol Biol Psychiatry, 44, 94-9.
NABER, N., VENKATESAN, P. P. & HAMILTON, G. A. (1982) Inhibition of dopamine beta-
hydroxylase by thiazoline-2-carboxylate, a suspected physiological product of D-amino
acid oxidase. Biochem Biophys Res Commun, 107, 374-80.
124
NACKLEY, A. G., SHABALINA, S. A., TCHIVILEVA, I. E., SATTERFIELD, K.,
KORCHYNSKYI, O., MAKAROV, S. S., MAIXNER, W. & DIATCHENKO, L.
(2006) Human catechol-O-methyltransferase haplotypes modulate protein expression
by altering mRNA secondary structure. Science, 314, 1930-3.
NAGAOKA, A. & LOVENBERG, W. (1976) Plasma norepinephrine and dopamine-beta-
hydroxylase in genetic hypertensive rats. Life Sci, 19, 29-34.
NAGATSU, I., KOBAYASHI, K., FUJII, T., KOMORI, K., SEKIGUCHI, K., TITANI, K.,
FUJITA, K. & NAGATSU, T. (1990) Antibodies raised against different oligopeptide
segments of human dopamine-beta-hydroxylase. Neurosci Lett, 120, 141-5.
NAGATSU, I., NAGATSU, T., MIZUTANI, K., UMEZAWA, H., MATSUZAKI, M. &
TAKEUCHI, T. (1971) Adrenal tyrosine hydroxylase and dopamine beta-hydroxylase
in spontaneously hypertensive rats. Nature, 230, 381-2.
NAGATSU, T., AYUKAWA, S. & UMEZAWA, H. (1968) Inhibition of dopamine beta-
hydroxylase by aquayamycin. J Antibiot (Tokyo), 21, 354-7.
NAGATSU, T., IKUTA, K., NUMATA, Y., KATO, T. & SANO, M. (1976) Vascular and
brain dopamine beta-hydroxylase activity in young spontaneously hypertensive rats.
Science, 191, 290-1.
NAGATSU, T., KATO, T., NUMATA, Y., KEIKO, I. & UMEZAWA, H. (1974) Serum
dopamine beta-hydroxylase activity in developing hypertensive rats. Nature, 251,
630-1.
NAGATSU, T. & UDENFRIEND, S. (1972) Photometric assay of dopamine- -hydroxylase
activity in human blood. Clin Chem, 18, 980-3.
NAKAMURA, S., KOSHIMURA, K., KATO, T., YAMAO, S., IIJIMA, S., NAGATA, H.,
MIYATA, S., FUJIYOSHI, K., OKAMOTO, K., SUGA, H. & ET AL. (1984)
Neurotransmitters in dementia. Clin Ther, 7 Spec No, 18-34.
NAKAMURA, T., YASUDA, H., OBAYASHI, A., TANABE, O. & MATSUMURA, S.
(1975) Phenopicolinic acid, a new microbial product inhibiting dopamine beta-
hydroxylase. J Antibiot (Tokyo), 28, 477-8.
NG, P. C. & HENIKOFF, S. (2006) Predicting the effects of amino acid substitutions on protein
function. Annu Rev Genomics Hum Genet, 7, 61-80.
NUNES, T., ROCHA, J. F., VAZ-DA-SILVA, M., IGREJA, B., WRIGHT, L. C., FALCAO,
A., ALMEIDA, L. & SOARES-DA-SILVA, P. (2010) Safety, Tolerability, and
Pharmacokinetics of Etamicastat, a Novel Dopamine-beta-Hydroxylase Inhibitor, in a
Rising Multiple-Dose Study in Young Healthy Subjects. Drugs R D, 10, 225-42.
O'CONNOR, D. T., CERVENKA, J. H., STONE, R. A., LEVINE, G. L., PARMER, R. J.,
FRANCO-BOURLAND, R. E., MADRAZO, I., LANGLAIS, P. J., ROBERTSON, D.
& BIAGGIONI, I. (1994) Dopamine beta-hydroxylase immunoreactivity in human
cerebrospinal fluid: properties, relationship to central noradrenergic neuronal activity
and variation in Parkinson's disease and congenital dopamine beta-hydroxylase
deficiency. Clin Sci (Lond), 86, 149-58.
O'CONNOR, D. T., LEVINE, G. L. & FRIGON, R. P. (1983) Homologous radio-immunoassay
of human plasma dopamine-beta-hydroxylase: analysis of homospecific activity,
circulating plasma pool and intergroup differences based on race, blood pressure and
cardiac function. J Hypertens, 1, 227-33.
125
OH, J., KIMCHI-SARFATY, C., KIM, I., SHERMAN, A., AMBUDKAR, S. & GOTTESMAN,
M. (2005) Functional characterization of SNP and haplotype of human MDR1 gene using
a vaccinia virus expression system. Clin Pharmacol Ther, 77, P24-P24.
OXENSTIERNA, G., EDMAN, G., ISELIUS, L., ORELAND, L., ROSS, S. B. & SEDVALL,
G. (1986) Concentrations of monoamine metabolites in the cerebrospinal fluid of twins
and unrelated individuals--a genetic study. J Psychiatr Res, 20, 19-29.
PACLT, I., KOUDELOVA, J., PACLTOVA, D. & KOPECKOVA, M. (2009) Dopamine beta
hydroxylase (DBH) plasma activity in childhood mental disorders. Neuro Endocrinol
Lett, 30, 604-9.
PADGETTE, S. R., HERMAN, H. H., HAN, J. H., POLLOCK, S. H. & MAY, S. W. (1984)
Antihypertensive activities of phenyl aminoethyl sulfides, a class of synthetic substrates
for dopamine beta-hydroxylase. J Med Chem, 27, 1354-7.
PAPP, B., PAL, C. & HURST, L. D. (2004) Metabolic network analysis of the causes and
evolution of enzyme dispensability in yeast. Nature, 429, 661-4.
PARK, J. H., WACHOLDER, S., GAIL, M. H., PETERS, U., JACOBS, K. B., CHANOCK, S.
J. & CHATTERJEE, N. (2010) Estimation of effect size distribution from genome-
wide association studies and implications for future discoveries. Nat Genet, 42, 570-5.
PARK, J. K., KIM, J. W., LEE, H. J., CHUNG, J. H., HA, E. Y., OH, D. J. & SONG, J. Y.
(2007) Dopamine beta-hydroxylase gene polymorphisms and psychotic symptoms in
schizophrenia. Am J Med Genet B Neuropsychiatr Genet, 144B, 944-5.
PARMLEY, W. W. (1995) Neuroendocrine changes in heart failure and their clinical relevance.
Clin Cardiol, 18, 440-5.
PAULANDER, W., ANDERSSON, D. I. & MAISNIER-PATIN, S. (2010) Amplification of
the gene for isoleucyl-tRNA synthetase facilitates adaptation to the fitness cost of
mupirocin resistance in Salmonella enterica. Genetics, 185, 305-12.
PFEFFER, M. A. & STEVENSON, L. W. (1996) Beta-adrenergic blockers and survival in heart
failure. N Engl J Med, 334, 1396-7.
PISANO, J. J., CREVELING, C. R. & UDENFRIEND, S. (1960) Enzymic conversion of p-
tyramine to p-hydroxyphenylethanolamine. Biochim Biophys Acta, 43, 566-8.
PISPA, J. P. & MACDONALD, E. (1980) Inhibition of dopamine-beta-hydroxylase by a
metabolite of pyrazole, 4-hydroxypyrazole, in vitro. FEBS Lett, 120, 64-6.
PLOTKIN, J. B. & KUDLA, G. (2011) Synonymous but not the same: the causes and
consequences of codon bias. Nat Rev Genet, 12, 32-42.
PRITCHARD, J. K. (2001) Are rare variants responsible for susceptibility to complex diseases?
Am J Hum Genet, 69, 124-37.
PRITCHARD, J. K. & COX, N. J. (2002) The allelic architecture of human disease genes:
common disease-common variant...or not? Hum Mol Genet, 11, 2417-23.
PUNIA, S., DAS, M., BEHARI, M., MISHRA, B. K., SAHANI, A. K., GOVINDAPPA, S. T.,
JAYARAM, S., MUTHANE, U. B., K, T. B. & JUYAL, R. C. (2010) Role of
polymorphisms in dopamine synthesis and metabolism genes and association of DBH
haplotypes with Parkinson's disease among North Indians. Pharmacogenet Genomics,
20, 435-41.
126
PUZYNSKI, S., RODE, A. & ZALUSKA, M. (1983) Studies on biogenic amine metabolizing
enzymes (DBH, COMT, MAO) and pathogenesis of affective illness. I. Plasma
dopamine-beta-hydroxylase activity in endogenous depression. Acta Psychiatr Scand,
67, 89-95.
RAINE, A. E. & CHUBB, I. W. (1977) Long term beta-adrenergic blockade reduces tyrosine
hydroxylase and dopamine beta-hydroxylase activities in sympathetic ganglia. Nature,
267, 265-7.
RAJASHEKHAR, B., FITZPATRICK, P. F., COLOMBO, G. & VILLAFRANCA, J. J. (1984)
Synthesis of several 2-substituted 3-(p-hydroxyphenyl)-1-propenes and their
characterization as mechanism-based inhibitors of dopamine beta-hydroxylase. J Biol
Chem, 259, 6925-30.
RATWATTE, H. A. & DOUGLAS, K. T. (1983) Photolabelling of dopamine-beta-hydroxylase
by bleomycin. Biochem Biophys Res Commun, 112, 273-8.
REA, R. F., BIAGGIONI, I., ROBERTSON, R. M., HAILE, V. & ROBERTSON, D. (1990)
Reflex control of sympathetic nerve activity in dopamine beta-hydroxylase deficiency.
Hypertension, 15, 107-12.
REICH, D. E. & LANDER, E. S. (2001) On the allelic spectrum of human disease. Trends
Genet, 17, 502-10.
RINNE, U. K. & SONNINEN, V. (1973) Brain catecholamines and their metabolites in
Parkinsonian patients. Treatment with levodopa alone or combined with a
decarboxylase inhibitor. Arch Neurol, 28, 107-10.
ROBERTSON, D., HAILE, V., PERRY, S. E., ROBERTSON, R. M., PHILLIPS, J. A., 3RD &
BIAGGIONI, I. (1991) Dopamine beta-hydroxylase deficiency. A genetic disorder of
cardiovascular regulation. Hypertension, 18, 1-8.
ROBINSON, P. D., SCHUTZ, C. K., MACCIARDI, F., WHITE, B. N. & HOLDEN, J. J.
(2001) Genetically determined low maternal serum dopamine beta-hydroxylase levels
and the etiology of autism spectrum disorders. Am J Med Genet, 100, 30-6.
ROCHA, J. F., VAZ-DA-SILVA, M., NUNES, T., IGREJA, B., LOUREIRO, A. I.,
BONIFACIO, M. J., WRIGHT, L. C., FALCAO, A., ALMEIDA, L. & SOARES-DA-
SILVA, P. (2011) Single-Dose Tolerability, Pharmacokinetics, and Pharmacodynamics
of Etamicastat (BIA 5-453), a New Dopamine {beta}-Hydroxylase Inhibitor, in Healthy
Subjects. J Clin Pharmacol.
ROMAN, T., SCHMITZ, M., POLANCZYK, G. V., EIZIRIK, M., ROHDE, L. A. & HUTZ,
M. H. (2002) Further evidence for the association between attention-
deficit/hyperactivity disorder and the dopamine-beta-hydroxylase gene. Am J Med
Genet, 114, 154-8.
ROSENBERG, R. C. (1983) Inhibition of dopamine beta-hydroxylase by 2-mercapto-1-
methylimidazole. Biochim Biophys Acta, 749, 276-80.
ROSENBERG, R. C., GIMBLE, J. M. & LOVENBERG, W. (1980) Inhibition of dopamine-
beta-hydroxylase by alternative electron donors. Biochim Biophys Acta, 613, 62-72.
RUSH, R. A. & GEFFEN, L. B. (1972) Radioimmunoassay and clearance of circulating
dopamine- -hydroxylase. Circ Res, 31, 444-52.
127
RUSH, R. A., KINDLER, S. H. & UDENFRIEND, S. (1975) Solid-phase radioimmunoassay
on polystyrene beads and its application to dopamine-beta-hydroxylase. Clin Chem, 21,
148-50.
RUSH, R. A., THOMAS, P. E., KINDLER, S. H. & UDENFRIEND, S. (1974) The interaction
of dopamine-beta-hydroxylase with concanavalin A and its use in enzyme purification.
Biochem Biophys Res Commun, 57, 1301-5.
RYCHLIK, J. L., GERBASI, V. & LEWIS, E. J. (2003) The interaction between dHAND and
Arix at the dopamine beta-hydroxylase promoter region is independent of direct
dHAND binding to DNA. J Biol Chem, 278, 49652-60.
SAMS, C. F. & MATTHEWS, K. S. (1984) Chemical modification of dopamine beta-
hydroxylase. Biochim Biophys Acta, 787, 61-70.
SANTRA, B. K., REDDY, P. A., NETHAJI, M. & CHAKRAVARTY, A. R. (2002) Structural
model for the Cu(B) site of dopamine beta-hydroxylase: crystal structure of a copper(II)
complex showing N(3)OS coordination with an axial sulfur ligation. Inorg Chem, 41,
1328-32.
SAPRU, M. K., RAO, B. S. & CHANNABASAVANNA, S. M. (1989) Serum dopamine-beta-
hydroxylase activity in clinical subtypes of depression. Acta Psychiatr Scand, 80, 474-8.
SAUTER, A. M., LEW, J. Y., BABA, Y. & GOLDSTEIN, M. (1977) Effect of
phenylethanolamine N-methyltransferase and dopamine-beta-hydroxylase inhibition on
epinephrine levels in the brain. Life Sci, 21, 261-6.
SAXENA, A. & FLEMING, P. J. (1983) Isolation and reconstitution of the membrane-bound
form of dopamine beta-hydroxylase. J Biol Chem, 258, 4147-52.
SCHANBERG, S. M., STONE, R. A., KIRSHNER, N., GUNNELLS, J. C. & ROBINSON, R.
R. (1974) Plasma dopamine beta-hydroxylase: a possible aid in the study and
evaluation of hypertension. Science, 183, 523-5.
SEIDAH, N. G., BENJANNET, S., WICKHAM, L., MARCINKIEWICZ, J., JASMIN, S. B.,
STIFANI, S., BASAK, A., PRAT, A. & CHRETIEN, M. (2003) The secretory
proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver
regeneration and neuronal differentiation. Proc Natl Acad Sci U S A, 100, 928-33.
SEO, H., YANG, C., KIM, H. S. & KIM, K. S. (1996) Multiple protein factors interact with the
cis-regulatory elements of the proximal promoter in a cell-specific manner and regulate
transcription of the dopamine beta-hydroxylase gene. J Neurosci, 16, 4102-12.
SEROVA, L. I., NOSTRAMO, R., VEERASIRIKUL, M., CAPPELL, D. B. & SABBAN, E. L.
(2011) Varied mechanisms of oestradiol-mediated regulation of dopamine beta-
hydroxylase transcription. J Neuroendocrinol, 23, 168-76.
SHENDURE, J. & JI, H. (2008) Next-generation DNA sequencing. Nat Biotechnol, 26, 1135-
45.
SLAMA, P., BOUCHER, J. L. & REGLIER, M. (2004) Aromatic N-hydroxyguanidines as new
reduction cosubstrates for dopamine beta-hydroxylase. Biochem Biophys Res Commun,
316, 1081-7.
SLAMA, P., BOUCHER, J. L. & REGLIER, M. (2009) N-Hydroxyguanidines oxidation by a
N3S copper-complex mimicking the reactivity of Dopamine beta-Hydroxylase. J Inorg
Biochem, 103, 455-62.
128
SMALL, K. S., HEDMAN, A. K., GRUNDBERG, E., NICA, A. C., THORLEIFSSON, G.,
KONG, A., THORSTEINDOTTIR, U., SHIN, S. Y., RICHARDS, H. B., SORANZO,
N., AHMADI, K. R., LINDGREN, C. M., STEFANSSON, K., DERMITZAKIS, E. T.,
DELOUKAS, P., SPECTOR, T. D. & MCCARTHY, M. I. (2011) Identification of an
imprinted master trans regulator at the KLF14 locus related to multiple metabolic
phenotypes. Nat Genet, 43, 561-4.
SMIGRODZKI, R., PARKS, J. & PARKER, W. D. (2004) High frequency of mitochondrial
complex I mutations in Parkinson's disease and aging. Neurobiol Aging, 25, 1273-81.
SOUTHAN, C., DEWOLF, W. E., JR. & KRUSE, L. I. (1990) Inactivation of dopamine beta-
hydroxylase by p-cresol: evidence for a second, minor site of covalent modification at
tyrosine 357. Biochim Biophys Acta, 1037, 256-8.
SOUTHAN, C. & KRUSE, L. I. (1989) Sequence similarity between dopamine beta-
hydroxylase and peptide alpha-amidating enzyme: evidence for a conserved catalytic
domain. FEBS Lett, 255, 116-20.
SRIVASTAVA, V., DESHPANDE, S. N. & THELMA, B. K. (2010) Dopaminergic pathway
gene polymorphisms and genetic susceptibility to schizophrenia among north Indians.
Neuropsychobiology, 61, 64-70.
SRIVASTAVA, V., VARMA, P. G., PRASAD, S., SEMWAL, P., NIMGAONKAR, V. L.,
LERER, B., DESHPANDE, S. N. & BK, T. (2006) Genetic susceptibility to tardive
dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene
polymorphisms. Pharmacogenet Genomics, 16, 111-7.
STANLEY, W. C., LEE, K., JOHNSON, L. G., WHITING, R. L., EGLEN, R. M. & HEGDE,
S. S. (1998) Cardiovascular effects of nepicastat (RS-25560-197), a novel dopamine
beta-hydroxylase inhibitor. J Cardiovasc Pharmacol, 31, 963-70.
STANLEY, W. C., LI, B., BONHAUS, D. W., JOHNSON, L. G., LEE, K., PORTER, S.,
WALKER, K., MARTINEZ, G., EGLEN, R. M., WHITING, R. L. & HEGDE, S. S.
(1997) Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent
and selective inhibitor of dopamine-beta-hydroxylase. Br J Pharmacol, 121, 1803-9.
STEINBERG, M. H. & ADEWOYE, A. H. (2006) Modifier genes and sickle cell anemia. Curr
Opin Hematol, 13, 131-6.
STEPHENS, J. C., SCHNEIDER, J. A., TANGUAY, D. A., CHOI, J., ACHARYA, T.,
STANLEY, S. E., JIANG, R., MESSER, C. J., CHEW, A., HAN, J. H., DUAN, J.,
CARR, J. L., LEE, M. S., KOSHY, B., KUMAR, A. M., ZHANG, G., NEWELL, W.
R., WINDEMUTH, A., XU, C., KALBFLEISCH, T. S., SHANER, S. L., ARNOLD,
K., SCHULZ, V., DRYSDALE, C. M., NANDABALAN, K., JUDSON, R. S.,
RUANO, G. & VOVIS, G. F. (2001) Haplotype variation and linkage disequilibrium in
313 human genes. Science, 293, 489-93.
STERNBERG, D. E., VAN KAMMEN, D. P., LERNER, P., BALLENGER, J. C., MARDER,
S. R., POST, R. M. & BUNNEY, W. E., JR. (1983) CSF dopamine beta-hydroxylase in
schizophrenia. Arch Gen Psychiatry, 40, 743-7.
STERNBERG, D. E., VANKAMMEN, D. P., LERNER, P. & BUNNEY, W. E. (1982)
Schizophrenia: dopamine beta-hydroxylase activity and treatment response. Science,
216, 1423-5.
STEWART, L. C. & KLINMAN, J. P. (1987) Characterization of alternate reductant binding and
electron transfer in the dopamine beta-monooxygenase reaction. Biochemistry, 26, 5302-9.
129
STRANDMAN, E., WETTERBERG, L., PERRIS, C. & ROSS, S. B. (1978) Serum dopamine-
beta-hydroxylase in affective disorders. Neuropsychobiology, 4, 248-55.
SUDA, H., TAKEUCHI, T., NAGATSU, T., MATSUZAKI, M., MATSUMOTO, I. &
UMEZAWA, H. (1969) Inhibition of dopamine beta-hydroxylase by 5-alkylpicolinic
acid and their hypotensive effects. Chem Pharm Bull (Tokyo), 17, 2377-80.
SUNYAEV, S., RAMENSKY, V. & BORK, P. (2000) Towards a structural basis of human
non-synonymous single nucleotide polymorphisms. Trends Genet, 16, 198-200.
SWANSON, D. J., ADACHI, M. & LEWIS, E. J. (2000) The homeodomain protein Arix
promotes protein kinase A-dependent activation of the dopamine beta-hydroxylase
promoter through multiple elements and interaction with the coactivator cAMP-
response element-binding protein-binding protein. J Biol Chem, 275, 2911-23.
SWANSON, D. J., ZELLMER, E. & LEWIS, E. J. (1998) AP1 proteins mediate the cAMP
response of the dopamine beta-hydroxylase gene. J Biol Chem, 273, 24065-74.
SYVERTSEN, C., MELO, T. B. & LJONES, T. (1987) Fluorescence studies on dopamine beta-
monooxygenase: effects of salts, pH changes, metal-chelating agents and Cu2+.
Biochim Biophys Acta, 914, 6-18.
TANG, Y., BUXBAUM, S. G., WALDMAN, I., ANDERSON, G. M., ZABETIAN, C. P.,
KOHNKE, M. D. & CUBELLS, J. F. (2006) A single nucleotide polymorphism at
DBH, possibly associated with attention-deficit/hyperactivity disorder, associates with
lower plasma dopamine beta-hydroxylase activity and is in linkage disequilibrium with
two putative functional single nucleotide polymorphisms. Biol Psychiatry, 60, 1034-8.
TANG, Y. L., EPSTEIN, M. P., ANDERSON, G. M., ZABETIAN, C. P. & CUBELLS, J. F.
(2007) Genotypic and haplotypic associations of the DBH gene with plasma dopamine
beta-hydroxylase activity in African Americans. Eur J Hum Genet, 15, 878-83.
TANNOCK, R. (1998) Attention deficit hyperactivity disorder: advances in cognitive,
neurobiological, and genetic research. J Child Psychol Psychiatry, 39, 65-99.
TAYLOR, C. S. & FLEMING, P. J. (1989) Conversion of soluble dopamine beta-hydroxylase
to a membrane binding form. J Biol Chem, 264, 15242-6.
TAYLOR, C. S., KENT, U. M. & FLEMING, P. J. (1989) The membrane-binding segment of
dopamine beta-hydroxylase is not an uncleaved signal sequence. J Biol Chem, 264, 14-6.
TERLAND, O. & FLATMARK, T. (1975) Ascorbate as a natural constituent of chromaffin
granules from the bovine adrenal medulla. FEBS Lett, 59, 52-6.
TERLAND, O. & FLATMARK, T. (2003) Anion- and pH-dependent activation of the soluble
form of dopamine beta-hydroxylase. Biochem J, 369, 675-9.
THELMA, B., SRIVASTAVA, V. & TIWARI, A. K. (2008) Genetic underpinnings of tardive
dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics, 9, 1285-306.
THIBAULT, C., LAI, C., WILKE, N., DUONG, B., OLIVE, M. F., RAHMAN, S., DONG, H.,
HODGE, C. W., LOCKHART, D. J. & MILES, M. F. (2000) Expression profiling of
neural cells reveals specific patterns of ethanol-responsive gene expression. Mol
Pharmacol, 58, 1593-600.
THOMAS, P. D. & KEJARIWAL, A. (2004) Coding single-nucleotide polymorphisms
associated with complex vs. Mendelian disease: evolutionary evidence for differences
in molecular effects. Proc Natl Acad Sci U S A, 101, 15398-403.
130
THOMAS, S. A., MATSUMOTO, A. M. & PALMITER, R. D. (1995) Noradrenaline is
essential for mouse fetal development. Nature, 374, 643-6.
TISCHLER, J., LEHNER, B., CHEN, N. & FRASER, A. G. (2006) Combinatorial RNA
interference in Caenorhabditis elegans reveals that redundancy between gene duplicates
can be maintained for more than 80 million years of evolution. Genome Biol, 7, R69.
TOGSVERD, M., WERGE, T. M., TANKO, L. B., BAGGER, Y. Z., HANSEN, T., QIN, G.,
CHRISTIANSEN, C. & RASMUSSEN, H. B. (2008) Association of a dopamine beta-
hydroxylase gene variant with depression in elderly women possibly reflecting
noradrenergic dysfunction. J Affect Disord, 106, 169-72.
TOKURIKI, N., STRICHER, F., SERRANO, L. & TAWFIK, D. S. (2008) How protein
stability and new functions trade off. PLoS Comput Biol, 4, e1000002.
TOWNES, S., TITONE, C. & ROSENBERG, R. C. (1990) Inhibition of dopamine beta-
hydroxylase by bidentate chelating agents. Biochim Biophys Acta, 1037, 240-7.
UMEZAWA, H., TAKEUCHI, T., MIYANO, K., KOSHIGOE, K. & HAMANO, H. (1973)
Letter: Fusaric acid derivatives: the effect on dopamine beta-hydroxylase. J Antibiot
(Tokyo), 26, 189.
VAN KAMMEN, D. P., MANN, L. S., STERNBERG, D. E., SCHEININ, M., NINAN, P. T.,
MARDER, S. R., VAN KAMMEN, W. B., RIEDER, R. O. & LINNOILA, M. (1983)
Dopamine-beta-hydroxylase activity and homovanillic acid in spinal fluid of
schizophrenics with brain atrophy. Science, 220, 974-7.
VITKUP, D., SANDER, C. & CHURCH, G. M. (2003) The amino-acid mutational spectrum of
human genetic disease. Genome Biol, 4, R72.
WALLACE, E. F., KRANTZ, M. J. & LOVENBERG, W. (1973) Dopamine-beta-hydroxylase:
a tetrameric glycoprotein. Proc Natl Acad Sci U S A, 70, 2253-5.
WALLACE, E. F., KRANTZ, M. J. & LOVENBERG, W. (1974) Subunit structure and
carbohydrate content of bovine adrenal dopamine-beta-hydroxylase. J Psychiatr Res,
11, 321-2.
WALLACE, E. F. & LOVENBERG, W. (1974) Studies on the carbohydrate moiety of
dopamine beta-hydroxylase: interaction of the enzyme with concanavalin A. Proc Natl
Acad Sci U S A, 71, 3217-20.
WANG, Z. & MOULT, J. (2001) SNPs, protein structure, and disease. Hum Mutat, 17, 263-70.
WEI, J., RAMCHAND, C. N. & HEMMINGS, G. P. (1997a) Possible control of dopamine
beta-hydroxylase via a codominant mechanism associated with the polymorphic (GT)n
repeat at its gene locus in healthy individuals. Hum Genet, 99, 52-5.
WEI, J., XU, H. M., RAMCHAND, C. N. & HEMMINGS, G. P. (1997b) Is the polymorphic
microsatellite repeat of the dopamine beta-hydroxylase gene associated with
biochemical variability of the catecholamine pathway in schizophrenia? Biol
Psychiatry, 41, 762-7.
WEINREICH, D. M., DELANEY, N. F., DEPRISTO, M. A. & HARTL, D. L. (2006)
Darwinian evolution can follow only very few mutational paths to fitter proteins.
Science, 312, 111-4.
131
WEINSHILBOUM, R. & AXELROD, J. (1971) Serum dopamine- -hydroxylase: decrease after
chemical sympathectomy. Science, 173, 931-4.
WEINSHILBOUM, R. M. (1978) Serum dopamine beta-hydroxylase. Pharmacol Rev, 30, 133-66.
WILCOX, G. & BEAVEN, M. A. (1976) A sensitive and specific tritium release assay for
dopamine-beta-hydroxylase (DbetaH) in serum. Anal Biochem, 75, 484-97.
WILSON, S. P. (1991) Insulin-like growth factor I enhances proenkephalin synthesis and
dopamine beta-hydroxylase activity in adrenal chromaffin cells. Life Sci, 49, 269-72.
WIMALASENA, K. & WIMALASENA, D. S. (1991a) Continuous spectrophotometric assays
for dopamine beta-monooxygenase based on two novel electron donors: N,N-dimethyl-
1,4-phenylenediamine and 2-aminoascorbic acid. Anal Biochem, 197, 353-61.
WIMALASENA, K. & WIMALASENA, D. S. (1991b) N,N,N',N'-tetramethyl-1,4-
phenylenediamine: a facile electron donor and chromophoric substrate for dopamine
beta-monooxygenase. Biochem Biophys Res Commun, 175, 920-7.
WONG, D. L., MASOVER, S. J. & CIARANELLO, R. D. (1981) Regulation of dopamine
beta-hydroxylase synthesis and degradation ascorbic acid stabilization of the enzyme
against tryptic proteolysis. J Biol Chem, 256, 695-700.
WOOD, J. G., JOYCE, P. R., MILLER, A. L., MULDER, R. T. & KENNEDY, M. A. (2002) A
polymorphism in the dopamine beta-hydroxylase gene is associated with "paranoid
ideation" in patients with major depression. Biol Psychiatry, 51, 365-9.
WU, C., LI, D., JIA, W., HU, Z., ZHOU, Y., YU, D., TONG, T., WANG, M., LIN, D., QIAO,
Y., CHANG, J., ZHAI, K., WEI, L., TAN, W., SHEN, H. & ZENG, Y. (2013)
Genome-wide association study identifies common variants in SLC39A6 associated
with length of survival in esophageal squamous-cell carcinoma. Nat Genet, 45, 632-8.
XU, H., FIRULLI, A. B., ZHANG, X. & HOWARD, M. J. (2003) HAND2 synergistically
enhances transcription of dopamine-beta-hydroxylase in the presence of Phox2a. Dev
Biol, 262, 183-93.
YAMAMOTO, K., CUBELLS, J. F., GELERNTER, J., BENKELFAT, C., LALONDE, P.,
BLOOM, D., LAL, S., LABELLE, A., TURECKI, G., ROULEAU, G. A. & JOOBER,
R. (2003) Dopamine beta-hydroxylase (DBH) gene and schizophrenia phenotypic
variability: a genetic association study. Am J Med Genet B Neuropsychiatr Genet,
117B, 33-8.
YANG, C., KIM, H. S., SEO, H., KIM, C. H., BRUNET, J. F. & KIM, K. S. (1998) Paired-like
homeodomain proteins, Phox2a and Phox2b, are responsible for noradrenergic cell-
specific transcription of the dopamine beta-hydroxylase gene. J Neurochem, 71, 1813-26.
YASHIMA, O., OZAWA, M., SATO, M., SUZUKI, K. & KIMURA, T. (1974) The role of
serum dopamine-beta-hydroxylase in essential hypertension. Jpn Circ J, 38, 1085-8.
YASUI, M., KIHIRA, T. & OTA, K. (1992) Calcium, magnesium and aluminum
concentrations in Parkinson's disease. Neurotoxicology, 13, 593-600.
ZABETIAN, C. P., ANDERSON, G. M., BUXBAUM, S. G., ELSTON, R. C., ICHINOSE, H.,
NAGATSU, T., KIM, K. S., KIM, C. H., MALISON, R. T., GELERNTER, J. &
CUBELLS, J. F. (2001) A quantitative-trait analysis of human plasma-dopamine beta-
hydroxylase activity: evidence for a major functional polymorphism at the DBH locus.
Am J Hum Genet, 68, 515-22.
132
ZANG, Y., DOLL, M. A., ZHAO, S., STATES, J. C. & HEIN, D. W. (2007) Functional
characterization of single-nucleotide polymorphisms and haplotypes of human N-
acetyltransferase 2. Carcinogenesis, 28, 1665-71.
ZELLMER, E., ZHANG, Z., GRECO, D., RHODES, J., CASSEL, S. & LEWIS, E. J. (1995) A
homeodomain protein selectively expressed in noradrenergic tissue regulates
transcription of neurotransmitter biosynthetic genes. J Neurosci, 15, 8109-20.
ZENKER, N., HUBBARD, L. S. & WRIGHT, J. (1988) Inhibition of dopamine beta-
hydroxylase by goitrin, a natural antithyroid compound. J Nat Prod, 51, 862-5.
ZHANG, E. Y., FU, D. J., PAK, Y. A., STEWART, T., MUKHOPADHYAY, N.,
WRIGHTON, S. A. & HILLGREN, K. M. (2004) Genetic polymorphisms in human
proton-dependent dipeptide transporter PEPT1: implications for the functional role of
Pro586. J Pharmacol Exp Ther, 310, 437-45.
ZHOU, X., ESPEY, M. G., CHEN, J. X., HOFSETH, L. J., MIRANDA, K. M., HUSSAIN, S.
P., WINK, D. A. & HARRIS, C. C. (2000) Inhibitory effects of nitric oxide and
nitrosative stress on dopamine-beta-hydroxylase. J Biol Chem, 275, 21241-6.
ZHU, Q., GE, D., MAIA, J. M., ZHU, M., PETROVSKI, S., DICKSON, S. P., HEINZEN, E.
L., SHIANNA, K. V. & GOLDSTEIN, D. B. (2011) A genome-wide comparison of the
functional properties of rare and common genetic variants in humans. Am J Hum Genet,
88, 458-68.